Novel Biologic Performs Well in IgG4-Related Disease

(MedPage Today) -- LONDON -- An investigational monoclonal antibody drug for immunoglobulin (Ig)G4-related disease called obexelimab substantially outperformed placebo in the phase III INDIGO trial, researchers reported, positioning it to take...
Source
MedPage Today
Opens original article in a new tab



